Quick Answer
GT Biopharma, Inc. reported Diluted EPS of $6.68 per share (loss) for fiscal year 2025.
GT Biopharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$6.68 | +3.7% |
| 2024 | -$6.94 | -23.0% |
| 2023 | -$5.64 | +71.3% |
| 2022 | -$19.66 | -281.0% |
| 2018 | -$5.16 | +40.0% |
| 2017 | -$8.60 | -107.2% |
| 2016 | $119.91 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.83 | +45.8% | -50.9% |
| June 30, 2025 | -$0.55 | +74.7% | -66.7% |
| March 31, 2025 | -$0.33 | +79.9% | +78.4% |
| September 30, 2024 | -$1.53 | +13.6% | +29.5% |
| June 30, 2024 | -$2.17 | -45.6% | -32.3% |
| March 31, 2024 | -$1.64 | -681.0% | +7.3% |
| September 30, 2023 | -$1.77 | -704.5% | -18.8% |
| June 30, 2023 | -$1.49 | -1390.0% | -609.5% |
- GT Biopharma, Inc. showed an increase of +3.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2016–2025 period, GT Biopharma, Inc.’s diluted eps has declined by 105.6% (from $119.91 per share to $6.68 per share (loss)).
- The most recent figure is from GT Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: